62P First-line (1L) camrelizumab plus chemotherapy (chemo) for advanced squamous non-small cell lung cancer (sqNSCLC): 4-yr update from the phase III CameL-sq trial

肿瘤科 医学 化疗 肺癌 内科学 癌症 基底细胞
作者
Caicun Zhou,Shengxiang Ren,Jie Chen,Xingxiang Xu,Ying Cheng,G. Chen,Yueyin Pan,Yong Fang,Q-M. Wang,Yunchao Huang,W. Yao,Ruoyu Wang,X. Li,W. Zhang,Ying Zhang,Sheng Hu,R-H. Guo,Dan Wang,Ziyi Wang,Xun‐Xi Lu
出处
期刊:ESMO open [Elsevier BV]
卷期号:9: 102641-102641 被引量:3
标识
DOI:10.1016/j.esmoop.2024.102641
摘要

In the phase III CameL-sq trial, camrelizumab + chemo as 1L treatment significantly extended PFS vs placebo + chemo in patients (pts) with advanced sqNSCLC. Here we report the outcomes 4 yrs after enrollment of the last pt. Eligible pts with previously untreated advanced sqNSCLC were randomized 1:1 to receive camrelizumab (200 mg) or placebo plus carboplatin (AUC 5) and paclitaxel (175 mg/m2) Q3W for 4-6 cycles, followed by maintenance therapy with camrelizumab or placebo. Pts allocated to the placebo arm were allowed to cross over to camrelizumab upon disease progression. 389 pts were randomized and treated (camrelizumab + chemo, n=193; placebo + chemo, n=196). As of Dec. 15, 2023, median time from randomization to data cutoff was 53.5 mo (range 47.5-61.0). Median OS was substantially prolonged with camrelizumab + chemo vs placebo + chemo (27.4 mo vs 15.5 mo; HR 0.56 [95% CI 0.45-0.72]); the OS benefit with camrelizumab + chemo was sustained, with a consistent improvement in OS rate of ∼20% at 2, 3, and 4 yrs (Table). 97 (49.5%) pts in the placebo + chemo arm crossed over to camrelizumab; analyses adjusted for cross-over effect with the Rank Preserving Structural Failure Time model further confirmed the OS benefits with camrelizumab + chemo (HR 0.35, 95% CI 0.27-0.47). Improvement in OS with camrelizumab + chemo vs placebo + chemo was seen regardless of baseline demographic and clinical characteristics; median OS was 19.8 mo vs 14.4 mo (HR 0.62, 95% CI 0.45-0.86) in the PD-L1 TPS <1% subgroup and 38.4 mo vs 20.1 mo (HR 0.56, 95% CI 0.40-0.81) in the PD-L1 TPS ≥1% subgroup. No new safety signals were identified.Table: 62POS outcomesCamrelizumab + chemo (n=193)Placebo + chemo (n=196)Median OS* (95% CI), mo27.4 (22.1-33.5)15.5 (13.4-18.4)HR (95% CI) †; p-value‡0.56 (0.45-0.72); p <0.0001OS rate* (95% CI), %1 yr75.0 (68.2-80.5)62.0 (54.8-68.4)2 yr53.4 (46.0-60.2)34.4 (27.8-41.1)3 yr41.6 (34.4-48.6)20.2 (14.8-26.2)4 yr33.9 (27.1-40.9)14.3 (9.7-19.9)* Kaplan-Meier method. † Stratified Cox proportional-hazards model stratified by smoking history (≥400 cigarette-yr vs <400 cigarette-yr or never), presence of liver or brain metastases at baseline (yes vs no), and sex (men vs women). ‡ One-sided p-value was calculated based on stratified log-rank test. Open table in a new tab * Kaplan-Meier method. † Stratified Cox proportional-hazards model stratified by smoking history (≥400 cigarette-yr vs <400 cigarette-yr or never), presence of liver or brain metastases at baseline (yes vs no), and sex (men vs women). ‡ One-sided p-value was calculated based on stratified log-rank test. The addition of camrelizumab to chemo continued to demonstrate clinically meaningful survival benefits with manageable toxicities after long-term follow-up; 4-yr OS rate was ∼20% higher in pts receiving camrelizumab + chemo, further supporting this regimen as a standard of care 1L treatment for advanced sqNSCLC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
丘比特的应助被唐唐采纳,获得10
1秒前
WuX完成签到,获得积分20
1秒前
完美世界的应助被gogogo采纳,获得10
1秒前
壮观的凝阳完成签到,获得积分10
1秒前
1秒前
2秒前
123完成签到,获得积分10
2秒前
seedcui完成签到,获得积分0
2秒前
白色洋桔梗完成签到 ,获得积分10
3秒前
library2025完成签到,获得积分10
3秒前
香蕉觅云的应助被杰杰小杰采纳,获得10
3秒前
乔凌云完成签到 ,获得积分10
4秒前
鱿鱼完成签到,获得积分10
4秒前
4秒前
CodeCraft的应助被WuX采纳,获得10
4秒前
道明嗣完成签到 ,获得积分10
5秒前
上官若男的应助被WYL采纳,获得10
6秒前
麒麟才子完成签到,获得积分10
6秒前
社会浩发布了新的文献求助10
6秒前
爽朗猫头鹰完成签到 ,获得积分10
6秒前
7秒前
炼丹完成签到 ,获得积分10
7秒前
余香的应助被常sc采纳,获得10
7秒前
水煮电吹风的应助被熊猫海采纳,获得10
7秒前
一颗煎蛋发布了新的文献求助10
7秒前
王思甜完成签到,获得积分20
8秒前
小二郎的应助被sqqx采纳,获得10
8秒前
lvxinda发布了新的文献求助10
8秒前
9秒前
包容咖啡完成签到 ,获得积分10
9秒前
阿wo关注了科研通微信公众号
9秒前
骆钧完成签到,获得积分10
9秒前
小蘑菇的应助被cp采纳,获得10
9秒前
H哈哈完成签到,获得积分10
9秒前
jie发布了新的文献求助10
9秒前
10秒前
典雅的寄真完成签到,获得积分20
10秒前
zjl发布了新的文献求助10
10秒前
辣辣完成签到,获得积分20
11秒前
传奇3的应助被曾经的清炎采纳,获得10
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175556
求助须知:如何正确求助?哪些是违规求助? 9567240
关于积分的说明 21791502
捐赠科研通 7770174
什么是DOI,文献DOI怎么找? 3431868
关于科研通互助平台的介绍 2556244
邀请新用户注册赠送积分活动 2477299